Biosimilar Monoclonal Antibody Market Size & Share, By Type (Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab, Others), Indication (Oncology, Autoimmune diseases, Others), End User (Hospitals, Cancer treatment centers, Others) - Growth Trends, Regional Insights (U.S., Japan, South Korea, UK, Germany), Competitive Positioning, Global Forecast Report 2025-2034

Report ID: FBI 6613| Published Date: Jan-2025| Format: PDF, Excel
Jump to Content
Market Outlook

Market Size and Growth Outlook

Biosimilar Monoclonal Antibody Market size is forecast to grow from USD 12.91 billion to USD 102.32 billion between 2025 and 2034, marking a CAGR of more than 23%. The expected industry revenue in 2025 is USD 15.58 billion.

Base Year Value (2024)
USD 12.91 billion
CAGR (2025-2034)
23%
Forecast Year Value (2034)
USD 102.32 billion
Historical Data Period
2019-2024
Largest Region
North America
Forecast Period
2025-2034

Get more details on this report

Request Free Sample Report
Snapshot

Biosimilar Monoclonal Antibody Market Intelligence Snapshot

Regional Market Dynamics

Segment Momentum

Market Expansion Drivers

Leading Market Participants

Forecast Snapshot

Global Market Forecast Snapshot

Market Outlook

Regional and Segment Outlook

Market Dynamics

Market Growth Drivers and Industry Trends

Growth Drivers & Opportunity: One of the primary growth drivers for the biosimilar monoclonal antibody market is the increasing prevalence of chronic diseases, including cancer and autoimmune disorders. As the global population ages and the incidence of these conditions rises, there is a growing demand for effective treatment options. Biosimilars offer a cost-effective alternative to expensive branded monoclonal antibodies, allowing for broader patient access to essential therapies. This increasing patient population is driving significant opportunities for market expansion as healthcare providers seek affordable treatment options. Another key growth driver is the supportive regulatory framework established by health authorities, which encourages the development and approval of biosimilars. Regulatory agencies, such as the FDA and EMA, have implemented guidelines that streamline the approval process for biosimilars, ensuring that these therapies can enter the market more efficiently. This reduced barrier to entry fosters competition among manufacturers, which not only lowers prices but also stimulates innovation within the industry. The overall positive regulatory environment is expected to continue to drive growth in the biosimilar monoclonal antibody market. Additionally, the rising healthcare costs associated with conventional monoclonal antibodies are prompting healthcare systems and payers to adopt biosimilars as a viable alternative. The high cost of treatment with branded monoclonal antibodies often leads to financial strain on healthcare budgets and limited patient access. Biosimilars present a solution by offering similar efficacy and safety profiles at reduced costs, thus encouraging adoption among healthcare providers and patients alike. This cost-saving potential is a significant growth driver in the market as stakeholders seek more sustainable healthcare solutions. Industry Restraints: Despite the promising growth outlook, the biosimilar monoclonal antibody market faces several restraints that could hinder its expansion. One major restraint is the complex manufacturing process involved in producing biosimilars, which requires advanced technology and expertise. The intricacies involved in replicating the biological properties of originator monoclonal antibodies can pose significant challenges for manufacturers. This complexity can lead to high production costs and potential quality control issues that may deter small and new entrants from participating in the market, ultimately limiting the growth potential of the industry. Another significant restraint is the varying degree of acceptance and adoption of biosimilars by healthcare professionals and patients. Concerns regarding the interchangeability and clinical equivalence of biosimilars compared to their reference products can lead to hesitation among prescribers and patients. Additionally, a lack of awareness and understanding of biosimilars may result in resistance among healthcare providers, who may prefer to prescribe established branded treatments. This reluctance can slow down the market penetration of biosimilars and limit their overall impact in providing affordable treatment solutions.

Explore Growth Opportunities

Request Free Sample Report
Regional Forecast

Regional Demand Dynamics

Biosimilar Monoclonal Antibody Market
Largest Region
North America
35% Market Share in 2024
North America The biosimilar monoclonal antibody market in North America is primarily driven by the high prevalence of chronic diseases, increasing healthcare costs, and growing acceptance of biosimilars among healthcare providers and patients. The United States leads the region due to its advanced healthcare infrastructure, significant investment in biopharmaceuticals, and favorable regulatory environment. The ongoing efforts to reduce healthcare expenditures and the introduction of cost-effective biosimilars are further propelling market growth. Canada is also observing an increase in biosimilar adoption, supported by government initiatives aimed at reducing drug costs and ensuring access to affordable treatments. Asia Pacific The Asia Pacific biosimilar monoclonal antibody market is experiencing rapid growth, fueled by rising healthcare expenditures, increasing prevalence of cancer, and supportive government policies promoting the use of biosimilars. China is emerging as a key player in the biosimilar market, driven by a large patient population, advancements in biomanufacturing, and significant investments from domestic and international companies. Japan and South Korea are also witnessing strong growth due to regulatory support, increasing awareness of biosimilars, and a growing demand for affordable biologic therapies. These countries are focusing on the development of high-quality biosimilars to enhance market penetration. Europe The European biosimilar monoclonal antibody market is characterized by stringent regulatory frameworks and a robust healthcare system. The United Kingdom, Germany, and France are leading markets in the region, driven by increasing pressure on healthcare budgets and the need for cost-effective therapies. The European Medicines Agency’s favorable guidelines for biosimilars and the successful entry of several biosimilars into the market have significantly enhanced market dynamics. The adoption of biosimilars in Europe is further supported by healthcare professionals’ growing familiarity with these products and positive clinical outcomes observed in biosimilar treatments. Enhanced competition among manufacturers is also expected to lower prices and increase accessibility to biologics across the region.
🔒 Need data on a specific country or region? Individual country/region reports are available at discounted pricing. Inquire Before Buying

Go beyond the chart, access full insights & data tables

Request Free Sample Report
Biosimilar Monoclonal Antibody Market Segment Analysis By Type The biosimilar monoclonal antibody market is primarily segmented by type, including Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab, and others. Adalimumab leads the market due to its extensive use in autoimmune diseases and its market exclusivity expiration, which has facilitated the entry of multiple biosimilars. Bevacizumab also holds a significant share as it is widely utilized in oncology for various cancers. Infliximab and Rituximab are gaining traction due to their applications in autoimmune conditions and hematological malignancies, respectively. Trastuzumab, largely used for HER2-positive breast cancer, represents a growing segment as the market recognizes the value of cost-effective alternatives. Collectively, these types reflect the increasing acceptance of biosimilars in therapeutic areas, driven by their efficacy, safety profiles, and cost advantages. By Indication The indication segment of the biosimilar monoclonal antibody market is categorized into oncology, autoimmune diseases, and others. Oncology dominates the market share, propelled by the rising cancer incidence worldwide and the growing number of biosimilar approvals for cancer treatment. The demand for affordable oncology therapeutics is a significant driver, as healthcare systems seek to manage rising treatment costs. Autoimmune diseases also contribute substantially to the market, with rising incidences of conditions such as rheumatoid arthritis and psoriasis leading to increased adoption of biosimilars. The “others” category encompasses conditions like ophthalmology and dermatology indications, indicating the expanding applications of biosimilars in diverse therapeutic areas beyond conventional uses. By End User The biosimilar monoclonal antibody market can be segmented by end user into hospitals, cancer treatment centers, and others. Hospitals serve as the primary end users, driven by their capacity to provide comprehensive healthcare services and manage diverse patient populations requiring biologic treatments. Cancer treatment centers are gaining prominence as specialized care facilitators, offering focused therapies for cancer patients, which boosts the demand for biosimilar monoclonal antibodies. The “others” segment includes outpatient clinics and pharmacies that are increasingly incorporating biosimilars into their treatment regimens. The overall trend towards value-based care and the need to reduce healthcare costs are prompting all end users to consider the benefits of biosimilars in delivering patient care.
Segment Sub-Segment Largest Segment Fastest Growing
Custom Research

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
Competitive Landscape

Competitive Landscape and Market Positioning

The competitive landscape in the Biosimilar Monoclonal Antibody Market is characterized by rapid growth, increased investment in research and development, and regulatory advancements that support the entry of biosimilars. Key players are vying for market share by leveraging their expertise in biotechnology and forming strategic collaborations with healthcare institutions. The demand for cost-effective treatment options for chronic diseases such as cancer and autoimmune disorders is driving competition. Additionally, market entrants face challenges from established originator biologics and the need for robust clinical data to demonstrate therapeutic equivalence. Companies are focusing on innovation, patient access initiatives, and navigating intellectual property rights to enhance their foothold in this dynamic market. Top Market Players 1 Amgen 2 Samsung Bioepis 3 Biocon 4 Sandoz 5 Celltrion 6 Mylan 7 Pfizer 8 Teva Pharmaceutical Industries 9 AbbVie 10 Fresenius Kabi
Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Report Customization

Customize Your Report

Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.

1 Custom Segments 2 Custom TOC 3 Related Reports

Biosimilar Monoclonal Antibody Market — Custom Segments

Segment Sub-Segment
No segment data available.

Biosimilar Monoclonal Antibody Market — Custom TOC

Custom Chapter Chapter Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
FAQ

Frequently Asked Questions

Testimonials

Our Clients

"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."

Project Manager
Siemens Healthcare

"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."

Research and Development (R&D) Manager
GC Biopharma

"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."

Quality Assurance Manager
Medtronic
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL
Healthcare & Medical Devices
Research Team Overview

This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team
10+Industry Verticals
100+Countries Analyzed
5-7Days Standard
Delivery
13.8K+Research Reports
Published
On-DemandCustomized Research
Available
6Months Analyst
Support
PDF + XLSReport Deliverables
Trust & Compliance
D&B D-U-N-S
GDPR & CCPA Compliant
ISO 9001 Certified (ISO 9001:2015)
SSL Encryption
Secure Payments
Confidential Handling
Research Intelligence
Primary Research Network
Secondary Sources
Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts
Research Workflow & Quality Assurance
01
Data Collection
Verified information gathered through primary and secondary research.
02
Data Triangulation
Cross-validation using multiple independent data sources.
03
Forecast Modelling
Market estimates developed using historical trends and analytical models.
04
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
05
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
06
Final Publication
Released after successful completion of the internal review process.
Report Coverage
Market Assessment
  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics
🏢 Competitive Intelligence
  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis
🚀 Future Outlook
  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →